DrugPatentWatch Database Preview

SYMLIN Drug Profile

« Back to Dashboard

When do Symlin patents expire, and what generic alternatives are available?

Symlin is a drug marketed by Astrazeneca Ab and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-two patent family members in sixteen countries.

The generic ingredient in SYMLIN is pramlintide acetate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pramlintide acetate profile page.

Summary for SYMLIN

International Patents:	32
US Patents:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	7
Clinical Trials:	19
Patent Applications:	32
Drug Prices:	Drug price information for SYMLIN
DailyMed Link:	SYMLIN at DailyMed

Pharmacology for SYMLIN

Drug Class	Amylin Analog
Mechanism of Action	Amylin Agonists

Synonyms for SYMLIN

25-L-proline-28-L-proline-29-L-proline-, acetate (salt), hydrate

25-L-Proline-28-L-proline-29-L-prolineamylin (human) acetate (salt), hydrate

AC0137

ACO137

AN-7554

LS-181996

LS-188084

Pramlintide [USAN]

Pramlintide acetate [USAN]

SCHEMBL238214

US Patents and Regulatory Information for SYMLIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-002	Sep 25, 2007		RX	Yes	No			Y	Y
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-003	Sep 25, 2007		RX	Yes	Yes			Y	Y
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-001	Mar 16, 2005		DISCN	No	No			Y	Y

Expired US Patents for SYMLIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-002	Sep 25, 2007
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-001	Mar 16, 2005
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-002	Sep 25, 2007
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-001	Mar 16, 2005
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-001	Mar 16, 2005
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-003	Sep 25, 2007
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-002	Sep 25, 2007

International Patents for SYMLIN

Country	Patent Number	Estimated Expiration
Japan	2006213716
Australia	714439
Norway	324405
Austria	205854
European Patent Office	0567626
Japan	2902115
Japan	H11152299